EC grants approval for Menarini’s breast cancer therapy
The European Commission granted approval for The Menarini Group’s Orserdu to treat patients with ER positive, HER2-negative breast cancer.
The European Commission granted approval for The Menarini Group’s Orserdu to treat patients with ER positive, HER2-negative breast cancer.
What's Your Reaction?
